Home › Compare › HUMDF vs EPRT

HUMDF vs EPRT: Dividend Comparison 2026

HUMDF yields 484.14% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUMDF wins by $47899.95M in total portfolio value
10 years
HUMDF
HUMDF
● Live price
484.14%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47900.01M
Annual income
$34,060,653,223.60
Full HUMDF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — HUMDF vs EPRT

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMDFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUMDF + EPRT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HUMDF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF
Annual income on $10K today (after 15% tax)
$41,152.26/yr
After 10yr DRIP, annual income (after tax)
$28,951,555,240.06/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, HUMDF beats the other by $28,951,544,325.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + EPRT for your $10,000?

HUMDF: 50%EPRT: 50%
100% EPRT50/50100% HUMDF
Portfolio after 10yr
$23950.04M
Annual income
$17,030,333,032.16/yr
Blended yield
71.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

HUMDF
No analyst data
Altman Z
3.9
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys
0
EPRT buys
0
No recent congressional trades found for HUMDF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMDFEPRT
Forward yield484.14% ✓3.92%
Annual dividend / share$2.00 ✓$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29% ✓
Portfolio after 10y$47900.01M ✓$63.4K
Annual income after 10y$34,060,653,223.60 ✓$12,840.73
Total dividends collected$46687.76M ✓$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HUMDF vs EPRT ($10,000, DRIP)

YearHUMDF PortfolioHUMDF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$59,114$48,414.43$11,205$505.18+$47.9K → HUMDF
2$330,728$267,475.81$12,672$682.46+$318.1K → HUMDF
3$1,752,431$1,398,551.73$14,490$930.48+$1.74M → HUMDF
4$8,800,812$6,925,711.29$16,786$1,282.69+$8.78M → HUMDF
5$41,922,789$32,505,919.38$19,753$1,791.56+$41.90M → HUMDF
6$189,569,894$144,712,509.91$23,677$2,541.64+$189.55M → HUMDF
7$814,403,207$611,563,420.90$29,008$3,672.99+$814.37M → HUMDF
8$3,326,842,984$2,455,431,552.18$36,463$5,425.08+$3326.81M → HUMDF
9$12,933,979,587$9,374,257,594.32$47,238$8,221.57+$12933.93M → HUMDF
10$47,900,011,382$34,060,653,223.60$63,385$12,840.73+$47899.95M → HUMDF

HUMDF vs EPRT: Complete Analysis 2026

HUMDF — Stock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

EPRT — REIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this HUMDF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHDHUMDF vs JEPIHUMDF vs OHUMDF vs KOHUMDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.